Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,274.05 -131.61 (-0.34%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,150.60 +6.47 (+0.08%) Bitcoin USD
57,708.26 -3,481.66 (-5.69%) CMC Crypto 200
1,236.78 -102.28 (-7.64%)
Gossamer Bio, Inc. (GOSS)
After hours:
| Previous close | 0.6963 |
| Open | 0.7350 |
| Bid | 0.7081 x 200 |
| Ask | 0.7224 x 100 |
| Day's range | 0.6542 - 0.7480 |
| 52-week range | 0.4530 - 1.8800 |
| Volume | |
| Avg. volume | 1,434,027 |
| Market cap | 160.615M |
| Beta (5Y monthly) | 1.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1800 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.72 |
Simply Wall St.Gossamer Bio Decline Means Insider Profits Down To US$17k
Insiders who bought Gossamer Bio, Inc. ( NASDAQ:GOSS ) stock lover the last 12 months are probably not as affected by...
Insider Monkey13 Best Biotech Stocks To Buy Under $20
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
Business WireGossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
SAN DIEGO, March 12, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors. Dr. Nathan is Medical Director of Inova’s Advanced Lung Disease Program and Lung Transplant
